Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupEndocrine and Neuroendocrine OncologyGastroenterologic OncologyGynecological OncologyHead and Neck OncologyThoracic TumorsTumor, regardless of entityDiseaseLung Carcinoma, Non-Small CellThyroid CancerTumor Biomarker DefinedSubgroupFGFR-alteredHER2+KRAS G12C-MutationMismatch Repair - deficient / Microsatellite Instability - high (dMMR/MSI-H)NTRK Gene FusionPOLE-alteredRET fusion positiveTMB - Tumor Mutational Burden highICD10C34.-C73MeSHNeoplasmsThyroid NeoplasmsSequenceGARNET: DOST500, Tumor Biomarker Defined, C1-4 (PID2632) -|- DOST1000, C5+ (PID2633)ChemotherapyChemo-substanceAdagrasibDostarlimabEntrectinibErdafitinibLarotrectinibPembrolizumabSelpercatinibTrastuzumab DeruxtecanTrastuzumab emtansineChemo-substanceAdagrasibDostarlimabEntrectinibErdafitinibLarotrectinibPembrolizumabSelpercatinibTrastuzumab DeruxtecanTrastuzumab emtansineChemo-substanceAdagrasibDostarlimabEntrectinibErdafitinibLarotrectinibPembrolizumabSelpercatinibTrastuzumab DeruxtecanTrastuzumab emtansineChemo-substanceAdagrasibDostarlimabEntrectinibErdafitinibLarotrectinibPembrolizumabSelpercatinibTrastuzumab DeruxtecanTrastuzumab emtansineNo. Substances1 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneGranisetronSupportive substanceBalanced Crystalloid SolutionDexamethasoneGranisetronSupportive substanceBalanced Crystalloid SolutionDexamethasoneGranisetronSupportive substanceBalanced Crystalloid SolutionDexamethasoneGranisetronNo. Substances123Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationRefractory diseaseSecond lineseveral possibleTherapy phaseInductionMaintenanceTherapy intentionpalliativeRisksAdrenal InsufficiencyAlopeciaAnemia Hb below 8g/dlAnemia Hb below 10g/dlAstheniaColitisConstipationDiarrheaDyspneaEdemaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Febrile NeutropeniaGastrointestinal ToxicityHand-Foot SyndromeHeadacheHepatotoxicityHyperphosphatemiaHypertensionHyperthyroidismHypokalemiaHyponatremiaHypothyroidismIncrease AminotransferasesInfectionsLymphopeniaMucositisNail ChangesNauseaNeuropathyNeutropeniaPneumoniaPneumonitisPruritusPyrexiaQTc Time ExtensionRashRenal FailureRetinopathySepsisThrombocytopenia below 50 000/µlVisual DisturbancesVomiting only studiesPublicationAuthorAndré T Bekaii-Saab TS Doebele RDrilon AJhaveri KLLe DTLi BTMarabelle APant SDiseaseLokal fortgeschrittener, nicht resezierbarer oder metastasierter solider Tumor, TMB-hoch, mindestens 1 Vortherapielinie, ECOG 0-1lokal fortgeschrittener oder metastasierter Tumor, unabhängig von der Entität, NTRK-Genfusion, ECOG 0-3Metastasierte, refraktäre, progrediente Mismatch-Repair Deficiency Karzinome, ECOG 0-1Nicht resezierbare, fortgeschrittene oder metastasierte Solide Tumoren, FGFR1–4 Mutation oder FusionRET-bedingte Tumoren, Zweitlinie oder höher, ECOG 0-2Solider Tumor, dMMR/MSI-HSolider Tumor, lokal fortgeschritten oder metastasiert, aktivierende Her2-Mutation, nach vorheriger Therapie, ECOG 0-1Solider Tumor metastasiert oder lokal fortgeschritten mit KRAS p.G12C Mutation, ECOG 0-1Solide Tumoren HER2 amplifiziert, außer Mamma-Ca oder AEG-Tumoren und Magen-Ca, ECOG 0-1Solide Tumoren mit NTRK-Fusion, TKI-naiv, ECOG 0-2OriginDepartment of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, USA, RAGNARRAGNARDepartment of Medical Oncology and Hematology, Mayo Clinic, Scottsdale, KRYSTAL-1 trialDivision of Medical Oncology, University of Colorado, Aurora, CO, USAJohns Hopkins Sidney Kimmel Comprehensive Cancer Center, BalimoreMemorial Sloan-Kettering Center, New York, USA, NCI-MATCH trial (EAY131)Memorial Sloan Kettering Cancer Center, 1275 York Ave., New YorkMemorial Sloan Kettering Cancer Center and Weill Cornell Medical College, LIBRETTO-001Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, DESTINY-PanTumor01 trialSaint-Antoine Hospital, INSERM, Unité Mixte de Recherche Scientifique 938, Paris, France, GARNET trialUniversite Paris-Saclay, Villejuif, France, KEYNOTE-158Protocols in Revision 11 protocols foundProtocols under revision.Adagrasib 600, Tumor Biomarker Defined (PID2668 V1.0)Dostarlimab 1000, Tumor Biomarker Defined, Cycle 5+ (PID2633 V1.0)Dostarlimab 500, Tumor Biomarker Defined, Cycle 1-4 (PID2632 V1.0)Entrectinib 600, Tumor Biomarker Defined (PID758 V1.0)Erdafitinib 8, Tumor Biomarker Defined (PID2630 V1.0)Larotrectinib 100, Tumor Biomarker Defined (PID1314 V1.0)Pembrolizumab 200, Tumor Biomarker Defined (PID1704 V1.0)Pembrolizumab 400, Tumor Biomarker Defined (PID1286 V1.0)Selpercatinib 160, Tumor Biomarker Defined (PID1732 V1.0)Trastuzumab Deruxtecan 5,4, Tumor Biomarker Defined (PID2652 V1.0)Trastuzumab Emtansine 3.6, Tumor Biomarker Defined (PID1677 V1.0)
